<DOC>
	<DOC>NCT01766167</DOC>
	<brief_summary>To conduct the following evaluations in Korean healthy male adult volunteers receiving a single and multiple doses of MP-424 tablets: - Pharmacokinetics of MP-424 after a single and multiple doses. - Safety and tolerability of single and multiple doses of MP-424.</brief_summary>
	<brief_title>Clinical Pharmacology Study of MP-424</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Korean healthy male volunteers aged 20 to 55 years Subjects with a BMI of &lt;18.5 or &gt;25.0, or body weight of &lt;50kg at prior examination Subjects who have had surgery that is known to affect gastrointestinal absorption of drugs (except for appendectomy and hernia surgery) Subjects who have had any evidence of cardiac disease at prior examination or who have a previous history of cardiac disease Subjects who are positive for HBs antigen, serologic tests for syphilis, HCV antibody, or HIV antibody at prior examination Subjects who have experienced symptoms of alcohol abuse or excessive alcohol ingestion Subjects who test positive on urinalysis for drug use (amphetamine, benzodiazepine, barbiturates, cannabinoid, cocaine, opiates, and methadone) at prior examination Subjects who do not agree to use a physical contraceptive method during the study period Subjects who do not agree to use contraceptive methods for 90 days after final administration of the study drug Subjects who have consumed grapefruit, Seville orange, star fruit, cranberry, or any processed food containing these fruits within 7 days before the commencement of study drug administration Subjects who have consumed health foods containing St John's Wort within 2 weeks before study drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Genotype 2</keyword>
</DOC>